Lesogaberan is a chemical compound that functions primarily as a selective modulator of the GABA (gamma-aminobutyric acid) receptor system, specifically targeting the GABA-B receptor subtype. It is characterized by its potential therapeutic applications in treating conditions such as anxiety and epilepsy due to its ability to enhance inhibitory neurotransmission in the central nervous system. The compound is known for its favorable pharmacokinetic properties, including good oral bioavailability and a manageable half-life, which contribute to its efficacy and safety profile. Lesogaberan has undergone various stages of clinical trials to assess its effectiveness and tolerability in humans. Its molecular structure includes specific functional groups that facilitate its interaction with biological targets, making it a subject of interest in neuropharmacology. As with many investigational drugs, ongoing research continues to elucidate its full range of effects and potential applications in clinical settings.

Lesogaberan

344413-67-8: AZD 3355, Lesogaberan, P-[(2R)-3-Amino-2-fluoropropyl]phosphinic acid, Phosphinic acid, [(2R)-3-amino-2-fluoropropyl]-, Phosphinic acid, P-[(2R)-3-amino-2-fluoropropyl]-

Lesogaberan: selective GABAB agonist, EC50 8.6 nM, Ki 5.1 nM in rats, weak GABAA affinity (Ki 1.4 μM).

CAS 344413-67-8: Lesogaberan

Lesogaberan

Ref: TR-L349570

Lesogaberan

Ref: TM-T15737